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The Impella Recover microaxial left ventricular assist
device reduces mortality for postcardiotomy failure:
A three-center experience
M. P. Siegenthaler, MD,a K. Brehm, MS,a T. Strecker, MD,d T. Hanke, MD,c A. No¨tzold, MD,c M. Olschewski, MSc,b
M. Weyand, MD,d H. Sievers, MD,c and F. Beyersdorf, MDa
Background: We evaluated patient outcomes and complications associated with the
microaxial Impella Recover left ventricular assist device (Impella Cardiosystems
AG, Aachen, Germany) for postcardiotomy low-output syndrome. This low-cost
device is inserted across the aortic valve through a 10-mm vascular graft sewn to the
ascending aorta.
Methods: Impella patients were compared with 198 patients treated with an intra-
operative intra-aortic balloon pump between January 2000 and December 2002.
Three risk scores were used: the Hausmann score, the Texas Heart Institute score,
and the Cleveland intensive care unit score. Between September 2001 and March
2003, 24 patients were treated with the Impella Recover for low-output syndrome.
Before device insertion, 21 could not be separated from cardiopulmonary bypass,
and 3 had postoperative hemodynamic instability despite high-dose catecholamines.
Sixteen were treated with the Impella and intra-aortic balloon pump and 8 with the
Impella alone (no intra-aortic balloon pump because of peripheral vascular disease
or because deemed unnecessary).
Results: No technical problems with device insertion occurred. Pump flow was 3.3
 0.7 L/min at 28,000 4500 RPM. Support time was 61 56 hours (range, 7-228
hours). Four devices required repositioning. One device failed (leaking purge line)
and was removed. Hemolysis was minimal (lactate dehydrogenase levels of 540 
260 U/dL for Impella survivors). Mortality for Impella patients was 54% (13/24),
similar to that for high-risk intra-aortic balloon pump patients (Hausmann score 2
[57%], intensive care unit score 2 [51%], Texas Heart Institute score 0.75
[55%], and cardiac index 2.3 [45%]). Cardiac output data were available in 19
Impella patients. Impella patients able to increase their cardiac output to 1 L/min or
more above the pump flow of the Impella Recover had a 10% (1/10) mortality,
versus 88% (8/9) in patients with a residual cardiac function of 1 L/min or less (P
 .001). Comparison of high-risk intra-aortic balloon pump patients with Impella
patients with residual cardiac function of 1 L/min or more showed a significant
reduction in mortality, regardless of the high-risk definition used. Residual cardiac
function was the strongest predictor of survival in Impella patients.
Conclusions: The Impella Recover device provides 3 to 4 L/min flow. It improves
survival in patients with low-output syndrome if the heart is able to pump 1 L/min
or more above device flow.
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Postcardiotomy low-output syndrome (LOS)remains one of the leading causes of deathafter cardiac surgical procedures.1,2 Death isusually attributed to multiorgan failure andnot to the underlying period of low cardiacoutput causing subsequent multiorgan failure.
We used the Impella Recover left ventricular assist device
(Impella Cardiosystems AG, Aachen, Germany) to treat
postcardiotomy LOS in 21 patients unable to be separated
from cardiopulmonary bypass and in 3 with hemodynamic
instability despite maximal catecholamine therapy before
insertion. This microaxial assist device with a diameter of
7.3 mm is inserted retrograde into the left ventricle across
the aortic valve through a 10-mm polyester graft
(Gelweave; Vascutek, Ltd, Renfrewshire, Scotland) sewn to
the ascending aorta. We evaluated patient outcomes and
complications associated with this device and analyzed the
possible effect on survival of this novel low-cost device by
using 2 risk scores developed specifically for intra-aortic
balloon pump (IABP) patients3,4 and an intensive care unit




In a retrospective review, data of all patients treated with an
intraoperative IABP from January 2000 to December 2002 were
analyzed. Patients who received a preoperative IABP, as well as
those with their IABP inserted 4 or more hours after the operation,
were excluded from the analysis. Of the 271 patients treated with
an intraoperative IABP, 15 were excluded because of the use of
extracorporeal membrane oxygenation or the use of another assist
device. Of the remaining 256 patients, 198 complete charts (77%)
were available for review, and 58 charts (23%) were incomplete or
missing. Hospital mortality was defined as any mortality that
occurred during the initial hospital stay.
Impella Patients
All 24 Impella devices were inserted between September 2001 and
March 2003. The device was used according to the attending
surgeon’s judgment, with no standard protocol for use of the
device. Most patients were unable to be separated from cardiopul-
monary bypass. All charts were available for review. Electronic
flow data were available in 13 Impella patients. In 8 patients, the
ICU flow sheet had hourly device flow rates recorded. Both cardiac
output data and device flow rates were present in 19 patients. All
postoperative events, including surgical and device-related com-
plications, were recorded. Estimated residual cardiac function in
patients with the Impella device was defined as follows:
Estimated residual cardiac function
cardiac output on the device device flow
Cardiac output was measured with a Swan-Ganz catheter (Arrow
International, Inc, Reading, Pa) at full device speed. Successful
weaning was defined as a stable patient who was alive for at least
72 hours after explantation of the Impella Recover device.
Impella Recover Left Ventricular Assist Device
The Impella Recover device is a microaxial left ventricular assist
device with a diameter of 6.4 mm at the body of the pump and a
7.3-mm diameter at the level of the outflow opening (Figure 1, A).
A small electric motor is built into the device, and the thin
(2.8-mm) cable leading to the device contains the electrical power
supply, which is connected to an external control unit as well as a
purge line connected to a purge perfusor, through which heparin
(concentration of 1000-2500 IU in 50 mL of glucose 40% solution)
is flushed continuously with a pressure of 300 to 700 mm Hg. The
heparin/glucose solution is delivered at the level of the pump, and
the patient does not need systemic anticoagulation in the early
postoperative phase. Once the bleeding has subsided, it is recom-
mended to heparinize the patient to an activated clotting time of
160 seconds or an activated partial thromboplastin time of 50 to 60
seconds. The glucose 40% solution is added to increase the vis-
cosity of the purge-line solution to achieve the required purge-line
pressure without giving large amounts of volume to the patient.
The usual amount of volume given is approximately 5 mL/h,
equivalent to a heparin dose of 250 U/h. The device can be set at
10 different speed levels, up to 33,000 RPM. At this speed,
depending on the afterload of the device, a pump performance of
approximately 3.5 to 5.0 L/min is possible, according to the manu-
facturer (Impella Cardiosystems AG). A memory chip built into the
controller console allows pump flow and pump speed data collection.
The different speed levels allow for gradual weaning to the lowest
setting (10,000 RPM), at which the net device flow is 0, because
the device overcomes only the mild aortic insufficiency it induces.
Even though the device is similar to the previously used He-
mopump (Medtronic, Inc, Minneapolis, Minn), there are technical
differences, including no cumbersome driveline, easier placement
with the pressure-differential display, monitoring of pump flow,
and a smaller size. A model for use via a femoral approach in the
cardiac catheter laboratory is also available.
Operative Technique
A 10-mm vascular graft was sewn to the ascending aorta (Figure
1, B), and the device was inserted retrograde across the aortic valve
from the ascending aorta into the left ventricle (Figure 1, C).
Positioning of the device occurred via a pressure-differential curve
on the device console, as well as with transesophageal echocar-
diographic control (Figure 1, C). The vascular graft with the device
was brought out of the skin either though the apex of the sternot-
omy incision or a small stab wound near the upper aspect of the
sternotomy. The sternum was left open with either a primary skin
closure or closure of the incision with an Epigard patch (Biovision
GmbH, Ilmenau, Germany). Once the patient was weaned from
ventricular support, the device was pulled out of the Dacron graft,
which was then either ligated flush with the ascending aorta or was
oversewn, followed by standard closure of the sternotomy.
Risk Scores
Table 1 shows the risk scores described by Baldwin and col-
leagues3 and Hausmann and colleagues4 for all IABP patients and
the risk score of Higgins and associates5 for patients who have had
cardiac operations. The 3 risk scores were applied to all IABP and
Impella patients. The risk scores were validated on our patient
cohort and were subsequently used to identify high-risk patients.
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Texas Heart Institute Score
The Texas Heart Institute (THI) score is based on preoperative
factors and postoperative pacemaker dependence (Table 1). All
data had to be present to be included in the analysis. The use of a
pacemaker is the strongest predictive factor for mortality in this
score; according to the authors, this is due to an extensive anterior
wall infarction involving the septum and leading to a complete
heart block. One of our centers used atrioventricular pacing in
virtually all patients who arrived in the cardiac surgical ICU. No
note was made if patients were truly pacemaker dependent. There-
fore, the THI score of this center had little predictive power and
was excluded from the analysis. Complete data were available in
98 IABP patients and in 18 Impella patients.
ICU Admission Score
This complex risk score includes multiple preoperative, intraoper-
ative, and postoperative parameters that are predictive of morbidity
and mortality (Table 1). Patients with more than 1 missing data
Figure 1. A, Dimensions of the pump head of the Impella Recover microaxial left ventricular assist device. The
device body is a flexible, wire-reinforced plastic tube to avoid potential mechanical damage by the pump head.
B, The Impella Recover system is secured to the 10-mm Dacron prosthesis. C, An intraoperative transesophageal
echocardiogram shows a correct position across the aortic valve.
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point were excluded from the analysis unless they had already
accumulated a score of 21 or more, which put them in the highest
risk category regardless of missing data. Data of the ICU admis-
sion score were available for analysis in 158 IABP patients and in
all 24 Impella patients.
Hausmann Score
This score is mainly based on patients’ hemodynamic status (Table
1). Patients with more than 1 possible score point missing were
excluded from the analysis. Because no left atrial pressure was
measured at our institutions, we substituted the pulmonary capil-
lary wedge pressure for the left atrial pressure used in the original
publication. Patients with a score of 3 or higher were included in
the analysis, because they were already in the highest-risk group
for mortality, regardless of missing data. Data were available for
analysis in 137 IABP patients and 20 Impella patients.
Statistical Analysis
Data are presented as mean  SD for quantitative variables and as
absolute and relative frequencies for qualitative variables. Group
comparisons were performed with Student t tests and Wilcoxon
rank sum tests for quantitative data, as appropriate, and with the
Fisher exact test for qualitative data. Logistic regression analysis
was used to calculate odds ratios for clinical covariates with
respect to survival. All significance tests were 2 sided. Data




Table 2 shows patient demographics and risk scores in
Impella and ICU patients. Patient demographics and preop-
erative risk profiles were similar; there was no difference
between the various risk scores between Impella and IABP
patients.
Surgical and Device-Related Data
There were no technical difficulties with device insertion. In
1 patient, who had a slightly calcified aortic valve, device
insertion was difficult, and several attempts were necessary
to get the device past the aortic valve. After implantation,
the skin was closed in 12 patients (skin and sternum in 6),
a skin-patch closure was used in 9, and in 3 patients the
wound closure was not specified. Four devices required
repositioning because they were advanced too far into the
left ventricle. This was noticed with insufficient pump flow
and the lack of a pressure-differential curve. One device
developed a leaking purge line, which led to malfunction of
the device. The device had to be removed.
Heparin was fully reversed after cardiopulmonary bypass
in 19 patients, and 5 had a partial reversal of their heparin.
Most patients were given low-dose heparin through the
Impella purge perfusor in the early postoperative period
until the chest tube drainage had slowed down, and they
were subsequently heparinized. Five surgical revisions for
bleeding were necessary in 4 Impella patients (5/24; 21%),
and no surgical source of the bleeding could be found in 3.
Anticoagulation and bleeding data of the Impella patients
are shown in Figure 2. The incidence of surgical revision for
bleeding in Impella patients was similar to that in high-risk
IABP patients, with a reoperation rate for bleeding of 8% to
14%, depending on the high-risk definition used (such as a
THI score 0.75, a Hausmann score 2, an ICU admission
score 21, an epinephrine dose 0.14 g · kg1 · min1,
or a cardiac index at 6 hours of 2.3 L · min1 · m2).
No clinically significant hemolysis was observed in the
Impella patients. Lactate dehydrogenase levels in Impella sur-




BSA 1.72 m2 1
Prior heart operation
One prior operation 1
Two or more prior operations 2
History of operation or angioplasty
for peripheral vascular disease
3
Age 70 y 3
Preoperative creatinine 1.0 mg/dL 4
Preoperative hematocrit 34% 5
Intraoperative factors
CPB time 160 min 3





Heart rate 100 beats/min 3
Cardiac index 2.1 L/min 3
Central venous pressure 17
mm Hg
4
Arterial bicarbonate 21 mmol/L 4
Calculation of ICU-score: sum of
all points
Hausmann score4
Epinephrine dose 0.5 g · kg1
· min1
2
Diuresis 100 mL/h 1
SVO2 60% 1
Left atrial pressure 15 mm Hg 1
Calculation of Hausmann score:
sum of all points
THI score3*
Pacing Yes  1, no  0
Age Value in years
Preoperative BUN Value in mg/dL
Sex Female  1, male  0
Calculation of THI score*
ICU, Intensive care unit; CBP, cardiopulmonary bypass; IABP, intra-aortic
balloon pump; SVO2, mixed venous oxygen saturation; BSA, body-surface
area; THI, Texas Heart Institute; BUN, blood urea nitrogen.
*Predicted mortality  exp (Bi/Xi)/[1  exp (Bi/Xi)], where BiXi 
3.44601 0.9079921 (pacing requirement) 0.0413888 (age) 0.0188389
(BUN)  0.6055711 (sex).
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vivors and nonsurvivors were 540  260 IU/L and 2747 
3070 IU/L, respectively, with no difference compared with the
lactate dehydrogenase levels of all IABP patients (n  198;
survivors, 612 387 IU/L; nonsurvivors, 1422 1696 IU/L;
P  .3). After weaning (16 patients), device removal was
followed by ligation or oversewing of the vascular graft in all
patients. No graft was entirely removed. Subsequently, heparin
anticoagulation was stopped. There were no sternal wound
infections in the Impella patients. Six (3%) of 198 IABP patients
required a surgical groin revision for bleeding or ischemia.
Device Flow Data
The average pump flow was 3.3  0.7 L/min in the first 12
hours. Figure 3 shows pump flow and device rotations per
minute for all patients. To evaluate maximal pump perfor-
mance, all patients with the device set at a speed of 27,000
RPM or more were analyzed, resulting in a maximal pump
flow of 3.5 0.5 L/min. Average support time was 61 56
hours (range, 7-228 hours): 60  37 hours (range, 22-123
hours) in survivors and 62  69 hours (range, 7-228 hours)
in nonsurvivors. Sixteen patients were weaned off the de-
vice, and successful weaning with a survival time of longer
than 72 hours was observed in 15 patients (63% of all
Impella patients). Weaning practice was variable. Average
weaning time was 19  13 hours (range, 2-42 hours), with
a tendency toward longer weaning times as experience with
the device grew. Weaning usually consisted of gradually
reducing the device flow as tolerated. The lowest pump
TABLE 2. Patient demographics
Variable Impella patients (n  24) IABP patients (n  198) P value
Preoperative parameters
Female sex 4/24 66/198 .109
Age (y) 66 8 68 10 .051
BSA (m2) 2.0 0.2 1.9 0.2 .047
Peripheral vascular disease 4/24 22/197 .3
Diabetes 4/24 43/198 .3
Creatinine (mg/dL) 1.1 0.5 1.1 0.4 .3
Blood urea nitrogen (mg/dL) 54 48 54 34 .154
Hematocrit (%) 38 5 39 10 .3
Previous cardiac operation 4/24 43/195 .3
Acute myocardial infarction 11/24 67/197 .265
Unstable angina 2/24 28/197 .3
Operative parameters
CPB time (min) 148 86 138 79 .3
Crossclamp time (min) 59 47 68 44 .223
CABG 19/24 134/197 .3
CABG  valve 2/24 33/197 .3
Valve 3/24 26/197 .3
Other 0/24 4/197 .3
Postoperative parameters
Cardiac index 6 h (L · min1 · m2) 2.5 0.8* 2.8 0.8 .101
Cardiac index 12 h (L · min1 · m2) 2.7 0.6* 2.9 0.8 .278
A-a gradient (mm Hg) 327 168 242 141 .019
Pacing 16/24 131/195 .3
Heart rate (beats/min) 100 18 102 18 .3
Arterial bicarbonate (mmol/L) 20 3 20 3 .3
CVP (mm Hg) 17 5 14 6 .033
PAWP at 6 h (mm Hg) 19 8 15 5 .040
Lactate at 6 h (mmol/L) 9 7 7 6 .3
Epinephrine 0.15 g · kg1 · min1 12/24 96/193 .3
Epinephrine 0.5 g · kg1 · min1 2/24 27/193 .3
Urine output at 8 h (mL/h) 73 57 176 202 .0001
Risk scores
THI score3 0.6 0.2 0.7 1.8 .116
Hausmann score4 1.5 1.0 1.0 1.1 .021
ICU score5 18.9 6.0 17.7 5.2 .272
A-a gradient, Alveolar-arterial oxygen gradient; BSA, body-surface area; CPB time, cardiopulmonary bypass time; CVP, central venous pressure; IABP,
intra-aortic balloon pump; residual cardiac function, cardiac output on the device (at full device speed)  device flow; PAWP, pulmonary artery wedge
pressure; CABG, coronary artery bypass graft; THI, Texas Heart Institute; ICU, intensive care unit.
*These values include the Impella Recover pump flow.
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setting with a net flow of 0 was tested only for a few
minutes at a time, and no patient remained on this minimal
setting for a prolonged period of time.
Risk Scores
All risk scores had significant power to predict mortality in
the cohort of IABP patients. Figure 4 shows the mortality rates
of IABP patients (with 95% confidence interval) estimated
from a logistic regression model by using each of the 3 risk
scores as a covariate. The only risk score that seemed to
correlate with mortality in Impella patients was the score
described by Hausmann and colleagues4 (Table 3; P  .051).
Mortality
Table 3 shows the analysis of factors potentially associated
with mortality in the Impella cohort. Patients with a residual
cardiac output of 1 L/min or more above the pump flow of
the Impella device (estimated residual cardiac function) had
a 10% (1/10) mortality, as opposed to 88% (8/9) in those
with a residual cardiac function of 1 L/min or less (P 
.001). Even though the cardiac index was also correlated
with mortality, the strongest predictor for mortality was the
residual cardiac function of the patients at 2, 6, and 12
hours. Nine of 10 patients with a residual cardiac output of
1 L/min or more survived and were discharged from the
hospital. Figure 5 displays the relationship of residual car-
diac function and survival.
The 10 patients with a residual cardiac function of 1
L/min or more had a significantly lower mortality compared
with high-risk IABP patients, defined by a THI score of 0.75
or more (n  49; mortality 55%; P  .013); a Hausmann
score of 2 or more (n  28; mortality 57%; P  .012); an
ICU admission score of 21 or more (n 49; mortality 51%;
P  .032); an epinephrine dose of 0.14 g · kg1 · min1
Figure 2. Bleeding and anticoagulation data of all Impella patients. A and B, Patients’ chest tube output and
transfusion requirements. C and D, Cumulative heparin dose given and results of the coagulation tests performed.
The triangles (Œ) represent patients who underwent a revision for bleeding; the other patients did not undergo
surgical revision. ACT, Activated clotting time; aPTT, activated partial thromboplastin time; PRBC, packed red
blood cells.
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or more, equivalent to high-dose epinephrine as defined by
Samuels and colleagues2 (n  96; mortality 44%; P 
.046); or a cardiac index at 6 hours of 2.3 L · min1 · m2
or less (n  43; mortality 42%; P  .039).
The 4 patients who did not survive their hospital stay but
were able to be successfully weaned from the device had a
residual cardiac output between 0 and 1 L/min. No patient
with a negative number of the residual cardiac function in
the early postoperative phase could be weaned off the
device.
In 6 patients, cardiogenic shock had been present for 4 or
more hours before Impella insertion. All of them died.
Causes of death in the Impella patients included multisys-
tem organ failure in 10, ventricular arrhythmia in 2, and an
intracranial hemorrhage in 1 patient that occurred 18 days
after removal of the device.
Discussion
We present an early experience of 24 patients treated with
the novel Impella Recover microaxial flow device for post-
operative LOS. We were able to distinguish 2 subgroups of
patients treated with the Impella Recover device. The first
subgroup, patients with a residual cardiac function of 1
L/min or more, had a significantly lower mortality (10%)
than high-risk IABP patients, regardless of the high-risk
definition used. On the basis of patients’ hemodynamics 2
hours after implantation, successful support and survival
with the Impella Recover device was predictable in 9 of 10
patients with a residual cardiac output of 1 L/min or more.
This is similar to another experience with the Hemopump
device, where postoperative hemodynamics was the only
predictive factor associated with patient survival.6 Contrib-
uting factors for better recovery in these patients have not
Figure 3. The average pump flow (A) and pump rotations (B) per minute of the Impella Recover.
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Figure 4. Mortality rates (with 95% confidence interval) estimated from a logistic regression model with the (A) ICU
score (n  158), (B) THI score (n  98), and (C) Hausmann score (n  137) as a covariate in IABP patients. The
solid boxes are the observed mortality rates within the different risk scores in the same population. The black
circle (●) shows the actual survival in Impella patients with a residual cardiac function of 1 L/min or more (SD),
and the black triangle (Œ) shows the survival of Impella patients with a residual cardiac function of 1 L/min or less
(SD).
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been well defined but possibly consist of partial left ven-
tricular unloading by the device, adequate whole-body per-
fusion, and fewer catecholamine requirements.
In the second subgroup of Impella patients, we were able
to identify patients who will not benefit from the Impella
Recover device. Patients with a residual cardiac function of
1 L/min or less had an 88% chance of death. This observa-
tion is likely due to 2 factors. First, the Impella Recover
device provides insufficient support in the presence of vir-
tually absent myocardial function; second, patients with
more extensive myocardial damage have less potential for
myocardial recovery. The likely failure of therapy and the
high probability of death in patients with a residual cardiac
function of 1 L/min or less were predictable in 6 of 7
available cardiac function measurements at 2 hours after
implantation. This seems important, because before leaving
the operating room the decision to implant a conventional
assist device can be made. Even without waiting 2 hours,
these patients can probably easily be identified if they do not
have any pulsatile output when CPB flow decreases to less
than 2 to 2.5 L/min despite adequate filling. Such patients,
to have a realistic chance of survival, should receive a
conventional assist device that is able to replace the entire
left heart function. A significant early increase in residual
cardiac function between 2 and 12 hours leading to survival
was observed in only 1 patient (Figure 5). One patient had
a significant decline in cardiac function between 6 and 12
hours after surgery, when he approached the cutoff point of
a residual cardiac function of 1 L/min; this ultimately led to
his death (Figure 5). If such a course were observed clini-
cally in the future, a switch to a different device could be
considered.
The surgical complication rate in Impella patients was
similar to that in high-risk patients treated with IABP alone,
which was lower than other experiences with left ventricular
assist support.7,8 The observed device-related complications
were minimal, with 1 device failure and 4 device repo-
sitions, all performed in the ICU. No observations of
familiar problems associated with axial flow technology
were made, including hemolysis and thromboembolic
events, and no wound- or device-related infections were
observed.









Creatinine 999.00 3.11-999.00 .026
Blood urea nitrogen 1.002 0.98-1.02 .3
Hematocrit 0.93 0.77-1.12 .3
Operative parameter
Cardiopulmonary bypass time 0.99 0.98-1.00 .174
Postoperative parameters
Cardiac index 6 h 0.34 0.10-1.17 .088
Cardiac index 12 h 0.064 0.01-0.78 .032
Residual cardiac function at 2 h 0.31 0.10-0.95 .041
Residual cardiac function at 6 h 0.27 0.08-0.87 .028
Residual cardiac function 1 L/min, 2 h 0.02 0.001-0.357 .008
Residual cardiac function 1 L/min, 6 h 0.01 0.001-0.260 .004
Residual cardiac function 1 L/min, 12 h 77.00 2.67-2222.00 .001
Pacing 21.0 1.94-227.2 .012
Heart rate 0.97 0.93-1.02 .290
Arterial bicarbonate 0.84 0.61-1.16 .29
Central venous pressure 1.10 0.92-1.33 .298
PAWP at 6 h 0.92 0.79-1.07 .295
Lactate at 6 h 1.14 0.96-1.36 .134
Epinephrine dose 0.5 g  kg1  min1 127.9 0.28-999.00 .121
Epinephrine dose 0.15 g  kg1  min1 6.00 1.02-35.37 .048
Urine output at 2 h 0.99 0.98-1.01 .237
Urine output at 8 h 0.98 0.96-1.00 .034
Risk scores
THI score3 5.61 0.06-542.40 .3
Hausmann score4 8.37 0.99-69.73 .051
ICU score5 0.99 0.88-1.16 .3
PAWP, Pulmonary artery wedge pressure; residual cardiac function, cardiac output on the device (at full device speed)  device flow; THI, Texas Heart
Institute; ICU, intensive care unit. The following variables had no demonstrable correlation with mortality (P .3): Preoperative factors—age, body-surface
area, peripheral vascular disease, diabetes, hematocrit, previous cardiac operation, and acute myocardial infarction; operative factors— crossclamp time
and postoperative revision; postoperative factors—lactate 2 h after surgery and alevolar-arterial oxygen gradient.
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It is interesting to note that the only risk score with
predictive power in Impella patients was the Hausmann
score (P  .051), despite a relatively low risk discrimina-
tion, as illustrated in Figure 4, C. This is most likely due to
its focus on patient hemodynamics, which seem to outweigh
most preoperative risk factors.
Our data do not support the indiscriminate use of this
device, because no evidence could be shown that the use of
the Impella Recover device in all patients with severe LOS
can reduce mortality compared with high-risk IABP pa-
tients. It has to be re-emphasized that the Impella patients
were substantially more ill, because they could not be sep-
arated from cardiopulmonary bypass or were hemodynam-
ically unstable despite high doses of catecholamine support.
Hence, the comparable overall mortality in all Impella pa-
tients and high-risk IABP patients gives only indirect evi-
dence for a potential patient benefit with indiscriminate use
of this device. Patients who become device dependent for
postcardiotomy LOS have a mortality rate of 75% to
80%.8-10 Even in a recently published revised screening
scale for left ventricular assist device recipients, the pres-
ence of postcardiotomy LOS was highly predictive of mor-
tality.11
Even when compared with all IABP patients, Impella
patients with a residual cardiac function of 1 L/min or more
seemed to have a survival benefit. Plotting their risk scores
on the risk score survival curves of all IABP patients (in-
cluding high- and low-risk patients) showed a higher sur-
vival than predicted, at the border of the 95% confidence
interval (Figure 4).
The stratification of the Impella patients into those with
a residual cardiac function of 1 L/min or more and those
with virtually absent myocardial function (residual heart
function1 L/min) allowed us to identify the patient cohort
with a dramatic survival benefit. This observation seems to
hold true despite the retrospective nature of this study, as
well as the lack of a standard protocol for use of the Impella
Recover device in this series. The analysis of this data
mandates a standardized protocol for implantation of the
Impella Recover device in patients with postcardiotomy
LOS. The indications for the use of this device should be
expanded for IABP patients with a high predicted mortality,
and this device should no longer be used in patients with
virtually absent myocardial function, because it is a true
assist device that is unable to replace the entire left ventric-
ular function.
In summary, the Impella Recover device is a low-cost
microaxial assist device that pumps 3 to 4 L/min and is
associated with a low complication rate. This study showed
a survival benefit in mortally ill patients with postcar-
diotomy LOS if the patient’s heart is able to contribute at
least 1 L/min to the cardiac output in the immediate post-
operative period.
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Discussion
Dr Ludwig K. von Segesser (Lausanne, Switzerland). Dr
Siegenthaler, I would like to congratulate you for this excellent
presentation on an important topic.
There has been significant progress in the development of axial
flow pumps for temporary assist, and you can see in the back-
ground [slide] the initial Hemopump for peripheral access, then in
the middle the one for central access, and finally the percutaneous
one. These pumps had a drive shaft, and I think one of the major
improvements with the current Impella device is that the drive
shaft has disappeared; the second major difference is that there are
sensors now available that give us some information about pump
positioning and flow.
I have 3 questions. You have already alluded to the bleeding
issue. I would like to know if there was a problem with platelet
consumption with this pump and if any of the deaths were related
to bleeding.
The second question is about thrombosis. There have been
emboli, I think, central emboli, but have the explanted pumps been
analyzed, and, if yes, were there any deposits?
Finally, what is your weaning protocol, or, in other words, what
would be the mean pump speed (RPM) required for 0 flow at a
mean arterial pressure of about 60 mm Hg?
Dr Siegenthaler. Thank you very much for those kind com-
ments and questions. Four Impella patients needed to go back to
the operating room because of bleeding. All required several
transfusions. In 3 of them, no surgical source of bleeding was
evident. The question of whether bleeding was responsible for the
patients’ deaths is difficult to answer. Certainly, no patient died
directly related to exsanguinating hemorrhage. Also, the incidence
of bleeding was no different in Impella patients than in high-risk
IABP patients. The cause of death in most of the 13 nonsurvivors
with the Impella pump was multisystem organ failure. Transfu-
sions certainly can be a contributing factor to such a syndrome and
therefore also could have been a factor leading to adverse out-
comes. We observed no platelet consumption.
As to thromboembolic events, we know from the carotid liter-
ature that surgeons do not have the same horizon to detect such
events as neurologists. I can tell you with certainty only that there
were no obvious strokes. One patient had a major intracranial
hemorrhage from which he died 18 days after successful removal
of the device, and we cannot rule out completely that he had bleeding
into a small and previously asymptomatic embolic area of his brain.
We looked at all the pumps when we explanted them, and we
could not see any residual fibrin or thrombi in the pumps. But this
information has to be viewed with caution, as there was no
systematic analysis of these pumps.
The pump is suitable for a slow weaning process, as it can be
set at 10 different speed levels, up to 33,000 RPM. At the lowest
pump setting, the pump just overcomes the mild aortic insuffi-
ciency that it causes. This allows assessment of the patient’s native
heart function at the bedside. Gradual weaning has been more
successful than our initial procedure, in which we evaluated the
ventricular performance with echocardiography at full or only
slightly reduced device speed. If satisfactory contractility was
found, we went to the operating room and tried to turn off the
pump. This approach was sometimes not well tolerated. We now
try to observe the patient in the ICU at a low pump setting after a
slow weaning process before proceeding to the operating room to
explant the device.
Dr O. Howard Frazier (Houston, Tex). This pump, of course,
is an extension and refinement of the Hemopump we first used in
1988. The Hemopump was powered by a cable, and its most
effective use was in the postcardiotomy patient. This was aborted
because the investors felt that there was not a big enough market,
and I have always felt that this was the 1 technology that would be
so important to directly unload the ventricle without requiring
heparinization or anticoagulation, which we did not use in the
immediate postoperative period with the Hemopump. Because the
Hemopump had a cable, we sewed the graft on to keep the cable
from fracturing.
Now, this pump is powered with an electric wire, and it is much
more effective from that standpoint. Do you think you could get rid
of the graft altogether, since those grafts are not inexpensive and
simply use a purse-string suture? The other question is, was
heparinization continued in the immediate postoperative period?
Dr Siegenthaler. Thank you very much for those questions.
Vascular grafts are expensive indeed; we pay about 500 Euro for
such a 10-mm Vascutek graft at our institution.
Nobody at our institutions has tried to insert the device without
a vascular graft, just by using a purse-string suture with a tourni-
quet. I could imagine that in a patient with a soft aorta this might
be actually possible, similarly to how we do it for thoracic intra-
aortic balloon pumps. But I think it would be risky to avoid the use
of a graft in the presence of a diseased aorta.
We use no anticoagulation therapy in the early postoperative
period until bleeding has subsided. Then we start heparin at 500
U/h and gradually increase it to a partial thromboplastin time of 50
to 60 seconds. The risk of pump thrombosis seems small even if
patients are not systemically anticoagulated, because the pump is
continuously purged with a low-dose heparin–containing solution.
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